Imatinib mesylate in the treatment of chronic myeloid leukaemia

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Imatinib mesylate (Gleevec™, Glivec®, formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukaemia (CML). The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML. This article will review the development of this molecularly targeted agent. The clinical trials with imatinib mesylate will be summarised along with the pharmacology of this agent. Despite the impressive responses seen in chronic-phase patients, numerous questions remain. For example, how durable will responses to imatinib mesylate be and is it necessary or possible to improve upon these results? Ongoing efforts to address these issues will be discussed.

Original languageEnglish (US)
Pages (from-to)963-971
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume4
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
bcr-abl Fusion Proteins
Clinical Trials
Imatinib Mesylate
Pharmacology
Pharmaceutical Preparations

Keywords

  • Bcr-abl
  • Chronic myeloid leukemia
  • Imatinib mesylate
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Imatinib mesylate in the treatment of chronic myeloid leukaemia. / Druker, Brian.

In: Expert Opinion on Pharmacotherapy, Vol. 4, No. 6, 01.06.2003, p. 963-971.

Research output: Contribution to journalArticle

@article{c472de55af3a482a951b3b47196cb1b0,
title = "Imatinib mesylate in the treatment of chronic myeloid leukaemia",
abstract = "Imatinib mesylate (Gleevec™, Glivec{\circledR}, formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukaemia (CML). The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML. This article will review the development of this molecularly targeted agent. The clinical trials with imatinib mesylate will be summarised along with the pharmacology of this agent. Despite the impressive responses seen in chronic-phase patients, numerous questions remain. For example, how durable will responses to imatinib mesylate be and is it necessary or possible to improve upon these results? Ongoing efforts to address these issues will be discussed.",
keywords = "Bcr-abl, Chronic myeloid leukemia, Imatinib mesylate, Tyrosine kinase inhibitor",
author = "Brian Druker",
year = "2003",
month = "6",
day = "1",
doi = "10.1517/14656566.4.6.963",
language = "English (US)",
volume = "4",
pages = "963--971",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Imatinib mesylate in the treatment of chronic myeloid leukaemia

AU - Druker, Brian

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Imatinib mesylate (Gleevec™, Glivec®, formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukaemia (CML). The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML. This article will review the development of this molecularly targeted agent. The clinical trials with imatinib mesylate will be summarised along with the pharmacology of this agent. Despite the impressive responses seen in chronic-phase patients, numerous questions remain. For example, how durable will responses to imatinib mesylate be and is it necessary or possible to improve upon these results? Ongoing efforts to address these issues will be discussed.

AB - Imatinib mesylate (Gleevec™, Glivec®, formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukaemia (CML). The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML. This article will review the development of this molecularly targeted agent. The clinical trials with imatinib mesylate will be summarised along with the pharmacology of this agent. Despite the impressive responses seen in chronic-phase patients, numerous questions remain. For example, how durable will responses to imatinib mesylate be and is it necessary or possible to improve upon these results? Ongoing efforts to address these issues will be discussed.

KW - Bcr-abl

KW - Chronic myeloid leukemia

KW - Imatinib mesylate

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0038009044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038009044&partnerID=8YFLogxK

U2 - 10.1517/14656566.4.6.963

DO - 10.1517/14656566.4.6.963

M3 - Article

C2 - 12783592

AN - SCOPUS:0038009044

VL - 4

SP - 963

EP - 971

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -